OBJECTIVE: This study was designed to investigate the effect of exogenous complement C3 administration on outcomes of sepsis and identify an optimal time for this therapy. MATERIALS AND METHODS: Colon ascendens stent peritonitis (CASP) was performed to induce sepsis in C57BL/6 mice, with sham-operated mice as control. Human purified C3 (HuC3, 1 mg) was administered via intraperitoneal injection, with 200 µl phosphate-buffered saline as control. Mice were categorized by the initiation time of HuC3 treatment. Survival, bacterial burden, vital organ damages, histology changes, and expression of C3 were compared between the groups. RESULTS: CASP-induced sepsis caused rapid complement C3 depletion and severe organ damage. Vital organs suffered from substantial bacterial loads. Exogenous C3 applied in the early stage of sepsis was associated with attenuated organ injuries, enhanced bacterial clearance, and improved survival. Exogenous C3 application promoted the synthesis of C3 in the early stage of sepsis. It appears that 6 h post-CASP surgery is the optimal time for HuC3 therapy. CONCLUSION: The study confirmed the positive effect of exogenous C3 on treatment of polymicrobial sepsis. C3 supplementation prior to the appearance of complement depletion could protect vital organs and its administration in the early stage of sepsis should be encouraged .
OBJECTIVE: This study was designed to investigate the effect of exogenous complement C3 administration on outcomes of sepsis and identify an optimal time for this therapy. MATERIALS AND METHODS: Colon ascendens stent peritonitis (CASP) was performed to induce sepsis in C57BL/6 mice, with sham-operated mice as control. Human purified C3 (HuC3, 1 mg) was administered via intraperitoneal injection, with 200 µl phosphate-buffered saline as control. Mice were categorized by the initiation time of HuC3 treatment. Survival, bacterial burden, vital organ damages, histology changes, and expression of C3 were compared between the groups. RESULTS: CASP-induced sepsis caused rapid complement C3 depletion and severe organ damage. Vital organs suffered from substantial bacterial loads. Exogenous C3 applied in the early stage of sepsis was associated with attenuated organ injuries, enhanced bacterial clearance, and improved survival. Exogenous C3 application promoted the synthesis of C3 in the early stage of sepsis. It appears that 6 h post-CASP surgery is the optimal time for HuC3 therapy. CONCLUSION: The study confirmed the positive effect of exogenous C3 on treatment of polymicrobial sepsis. C3 supplementation prior to the appearance of complement depletion could protect vital organs and its administration in the early stage of sepsis should be encouraged .
Authors: J W Olivier van Till; Suzanne Q van Veen; Oddeke van Ruler; Bas Lamme; Dirk J Gouma; Marja A Boermeester Journal: Shock Date: 2007-11 Impact factor: 3.454
Authors: N Zantl; A Uebe; B Neumann; H Wagner; J R Siewert; B Holzmann; C D Heidecke; K Pfeffer Journal: Infect Immun Date: 1998-05 Impact factor: 3.441
Authors: M B Fischer; A P Prodeus; A Nicholson-Weller; M Ma; J Murrow; R R Reid; H B Warren; A L Lage; F D Moore; F S Rosen; M C Carroll Journal: J Immunol Date: 1997-07-15 Impact factor: 5.422
Authors: John G Younger; David O Bracho; Hangyul M Chung-Esaki; Moonseok Lee; Gurpreet K Rana; Ananda Sen; Alan E Jones Journal: Acad Emerg Med Date: 2010-04 Impact factor: 3.451
Authors: Michael Mihlan; Anna M Blom; Koba Kupreishvili; Nadine Lauer; Kristin Stelzner; Frida Bergström; Hans W M Niessen; Peter F Zipfel Journal: FASEB J Date: 2011-08-19 Impact factor: 5.191
Authors: Robert Silasi-Mansat; Hua Zhu; Narcis I Popescu; Glenn Peer; Georgia Sfyroera; Paola Magotti; Lacramioara Ivanciu; Cristina Lupu; Tom E Mollnes; Fletcher B Taylor; Gary Kinasewitz; John D Lambris; Florea Lupu Journal: Blood Date: 2010-05-13 Impact factor: 22.113
Authors: Vladimíra Fejfarová; Alexandra Jirkovská; Michal Dubský; Frances Game; Jana Vydláková; Alena Sekerková; Jana Franeková; Monika Kučerová; Ilja Stříž; Vladimír Petkov; Robert Bém; Veronika Wosková; Andrea Němcová; Jelena Skibová Journal: J Diabetes Res Date: 2016-12-05 Impact factor: 4.011